Immunic, Inc. (IMUX) Stock Price & Analysis
Immunic, Inc. (IMUX) closed at USD 7.1 on Thursday, October 15, 2026, up 6.61% on the day. The US market is currently closed; this is not a live price.
The prior close was USD 6.66; the Oct 15, 2026 session ranged USD 6.59–7.14 on volume of 285,101 shares. Market capitalization is $96.88M, with a 52-week range of USD 5.06–17.43 (NCM). Source: Nexqual, retrieved October 16, 2026 at 05:22 UTC.
Also available as compact Markdown for AI agents: nexqual.com/IMUX.md
Key facts (IMUX)
- Analysts: Buy (mean 2.00 on a 1–5 scale) (12 analysts), mean target USD 43.09 (range 22–85).
- Total return with dividends: 1Y -13.0% vs S&P 500 +18.1%; 5Y -91.8% vs S&P 500 +85.1%.
- Next earnings: 2026-11-13, EPS estimate USD -0.96, revenue estimate $0K.
Analysts (IMUX)
Consensus Buy (mean 2.00 on a 1–5 scale), 12 analysts; mean target USD 43.09 (low 22, high 85).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-09-10 | Wedbush | Reiterated | Outperform | $45 |
| 2026-09-10 | HC Wainwright & Co. | Reiterated | Buy | $22 |
| 2026-08-17 | Wedbush | Initiated | Outperform | $45 |
Total return (dividends reinvested) (IMUX)
| 1Y (from 2025-10-16) | 5Y (from 2021-10-11) | |
|---|---|---|
| Total return | -13.0% | -91.8% |
| S&P 500 (SPY) | +18.1% | +85.1% |
| Per year | -13.0% | -39.3% |
| Volatility (annualized) | 82.1% | 117.6% |
| Max drawdown | -60.6% (Aug 2026→Oct 2026) | -95.9% (Feb 2022→Dec 2025) |
Key Statistics (as of October 16, 2026 at 05:22 UTC)
| Price | USD 7.1 |
|---|---|
| Change | ▲ 6.61% (up) |
| Previous Close | USD 6.66 |
| Open | USD 6.65 |
| Day Range | USD 6.59 – 7.14 |
| 52-Week Range | USD 5.06 – 17.43 |
| Volume | 285,101 shares |
| Market Cap | $96.88M |
| Exchange | NCM |
Technical Analysis (IMUX)
Nexqual's technical model rates IMUX "SELL" based on 1 bullish and 5 bearish signals across 127 daily candles, as of October 16, 2026 at 05:22 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 26 (oversold) |
| vs SMA50 | Below (USD 12.07) |
| MACD | -1.37 (negative) |
Analyst Ratings (IMUX)
Wall Street analysts rate IMUX "Buy" based on 12 analysts, with a mean price target of USD 43.09 (range USD 22–85), per Nexqual as of October 16, 2026 at 05:22 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 12 |
| Mean Target | USD 43.09 |
| High Target | USD 85 |
| Low Target | USD 22 |
| Buy / Hold / Sell | 12 / 0 / 0 |
Earnings (IMUX)
| Next Earnings Date | 2026-11-13 |
|---|---|
| EPS Estimate | USD -0.96 |
| Revenue Estimate | $0 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD -0.8 vs est -1.17 ▲ beat |
| 2026-03-31 | USD -1.08 vs est -0.96 ▼ miss |
| 2025-12-31 | USD -0.7 vs est -1.11 ▲ beat |
| 2025-09-30 | USD -1.3 vs est -1.77 ▲ beat |
Source: Nexqual, October 16, 2026 at 05:22 UTC.
Financials & Fundamentals (IMUX)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -138.17% |
| Debt / Equity | 0 |
| Current Ratio | 5.05 |
| Total Cash | $155.10M |
| Total Debt | $567,000 |
Source: Nexqual, October 16, 2026 at 05:22 UTC.
Financial Health Score (IMUX)
Nexqual rates Immunic, Inc.'s overall financial health "Mixed" across five dimensions, as of October 16, 2026 at 05:22 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Strong — $155M cash, no debt |
| Cash Flow | Weak — Operating cash flow -$88M (TTM) |
| Efficiency | Critical — ROE -138%, ROA -66.8% |
Ownership (IMUX)
| Insider Ownership | +0.97% |
|---|---|
| Institutional Ownership | +71.18% |
| Shares Outstanding | 13.64M |
| Float | 12.01M |
| Short % of Float | +16.10% |
Source: Nexqual, October 16, 2026 at 05:22 UTC.
Leadership (IMUX)
Immunic, Inc. is led by Erik Lundgren (age 47), CEO & Director, per Nexqual as of October 16, 2026 at 05:22 UTC.
| CEO & Director | Erik Lundgren (age 47) |
|---|---|
| COO & President | Jason Tardio (age 48) |
| Chief Financial Officer | Glenn Whaley (age 57) |
| Co-Founder & Chief Scientific Officer | Hella Kohlhof (age 52) |
| Vice President of Investor Relations & Communications | Jessica Breu |
Major Backers & Investors (IMUX)
Notable institutional backers of Immunic, Inc. include Aberdeen Group plc, BVF Inc., Millennium Management, according to Nexqual as of October 16, 2026 at 05:22 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Aberdeen Group plc | 6.04% |
| BVF Inc. | 5.61% |
| Millennium Management | 5.43% |
| Avidity Partners Management, LP | 4.91% |
| Braidwell LP | 4.73% |
| Laurion Capital Management, LP | 4.47% |
| Jones Hill Capital LP | 3.96% |
| abrdn Healthcare Investors | 3.47% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 8.28% |
Source: Nexqual, October 16, 2026 at 05:22 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| RYTM | Rhythm Pharmaceuticals, Inc. | USD 87.97 | ▲ 1.57% |
| BLTE | Belite Bio, Inc | USD 152.62 | ▲ 0.49% |
| IOVA | Iovance Biotherapeutics, Inc. | USD 14.72 | ▲ 1.52% |
| PRAX | Praxis Precision Medicines, Inc | USD 248.24 | ▲ 2.01% |
| IONS | Ionis Pharmaceuticals, Inc. | USD 44.12 | ▲ 4.11% |
| SYRE | Spyre Therapeutics, Inc. | USD 80.1 | ▼ 0.44% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 16, 2026 at 05:22 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt